{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00030235", "CSN": null, "TRF": "ORD_1648390_01", "MRN": "7948825", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1334248", "clinicalId": "1335595", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1648390_01", "SampleName": "US1572225.01", "Version": "0", "Sample": {"FM_Id": "ORD_1648390_01", "SampleId": "US1572225.01", "BlockId": "S112-25343G", "TRFNumber": "ORD_1648390_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_06_09", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "20", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10160", "MRN": "7948825", "FullName": "\u6797\u937e\u6dd1\u6afb", "FirstName": "Shu Ying", "LastName": "Lin Chung", "SubmittedDiagnosis": "Skin melanoma", "Gender": "Female", "DOB": "1952_04_20", "OrderingMD": "\u5468\u5609\u63da", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lymph Node", "CollDate": "2023_05_31", "ReceivedDate": "2023-06-26 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Melanoma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "BRAF"}, {"Gene": "KIT"}]}, "Summaries": {"alterationCount": "17", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "3"}, "VariantProperties": {"VariantProperty": [{"geneName": "ALK", "isVUS": "true", "variantName": "A1274T"}, {"geneName": "DNMT3A", "isVUS": "true", "variantName": "S337L"}, {"geneName": "KDM5A", "isVUS": "true", "variantName": "T269N"}, {"geneName": "LTK", "isVUS": "true", "variantName": "G213_A214insGGG"}, {"geneName": "PARP1", "isVUS": "true", "variantName": "A625T"}, {"geneName": "PIK3C2G", "isVUS": "true", "variantName": "E88G,R981C"}, {"geneName": "SNCAIP", "isVUS": "true", "variantName": "D451N"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "A2800V"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "NRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "Q61R", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "16.4", "isEquivocal": "false", "name": "Q61R"}}, "Interpretation": "NRAS encodes a member of the RAS family of small GTPases that mediate transduction of growth signals. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways (Pylayeva_Gupta et al., 2011; 21993244). NRAS alterations affecting amino acids G12, G13, G60, Q61, as well as mutations I24N, T50I, T58I, and A146T have been characterized as activating and oncogenic (Buhrman et al., 2010; 20194776, Cirstea et al., 2010; 19966803, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Janakiraman et al., 2010; 20570890, Lukman et al., 2010; 20838576, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Runtuwene et al., 2011; 21263000, Scheffzek et al., 1997; 9219684, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Gremer et al., 2011; 20949621, Altmuller et al., 2017; 28594414, Hiippala et al., 2016; 26888048). NRAS mutations have been reported in ~20% of melanoma cases (7_33% in various studies), with similar frequency in primary and metastatic samples (Lee et al., 2011; 21166657, Xia et al., 2014; 24755198, Puig_Butill\u00e9 et al., 2013; 23362874, Smalley, 2010; 19571822, Pylayeva_Gupta et al., 2011; 21993244, Monzon and Dancey, 2012; 22419879, Platz et al., 2008; 19383313, Omholt et al., 2002; 12429636, Ekedahl et al., 2013; 23855428, Dutton_Regester et al., 2013; 23890154). Similar frequencies of NRAS mutations have been reported in cutaneous melanoma, mucosal melanoma, acral lentiginous melanoma (ALM), conjunctival melanoma, vulvar melanoma, vaginal melanoma and melanoma of unknown primary (Lee et al., 2011; 21166657, Xia et al., 2014; 24755198, Jacob et al., 2012; 22180178, Zebary et al., 2013; 23993026, Griewank et al., 2013; 23633454, Uhara et al., 2014; 23739925, Wong et al., 2005; 15917418, Aulmann et al., 2014; 24603591, Wang et al., 2019; 31578274). Conflicting findings have been reported regarding the prognostic significance of NRAS mutation in the context of melanoma, with some studies noting significant adverse impact on clinico_pathological features as well as overall and/or melanoma_free survival (Jacob et al., 2012; 22180178, Devitt et al., 2011; 21615881, Birkland et al., 2013; 23673558, Mann et al., 2013; 22931913, Si et al., 2012; 21788131, Wang et al., 2019; 31578274), whereas other studies reported no significant impact on survival (Rutkowski et al., 2014; 24959217, Carlino et al., 2014; 24918823, Ekedahl et al., 2013; 23855428, Eqberts et al., 2014;24276025, Wu et al., 2014; 25048604, Griewank et al., 2013; 23633454). On the basis of clinical evidence in hematologic malignancies (Slosberg et al., 2018; 29765547, Ravandi et al., 2015; 26657199, Maiti et al., 2019; 30635233, Khanna et al., 2015; 26870618, Heuck et al., 2016; 26228812, Abdel_Wahab et al., 2014; 24589925, Holkova et al., 2016; 26446942) and solid tumors (Slosberg et al., 2018; 29765547, Wu et al., 2018; WCLC Abstract P1.01_97, Dummer et al., 2017; 28284557, Ascierto et al., 2013; 23414587, van Herpen et al., 2019; 30956763, van Herpen et al., 2014; 30956763), NRAS activating alterations may predict sensitivity to MEK inhibitors, such as trametinib, cobimetinib, binimetinib, and selumetinib. A Phase 3 study of the MEK inhibitor binimetinib in patients with NRAS_mutated melanoma who were previously untreated or had progressed on immunotherapy reported a significant increase in median progression_free survival as compared to dacarbazine (2.8 vs. 1.5 months) (Dummer et al., 2017; 28284557). In a nonrandomized Phase 2 study of binimetinib in 30 patients with NRAS_mutated melanoma, 20% (6/30) had a PR and 63% (19/30) had an SD, and the size of brain metastases was reduced in 2 patients treated with binimetinib (Ascierto et al., 2013; 23414587). A Phase 1 study of the ERK1/2 inhibitor ulixertinib reported PRs in 18% (3/17) and SDs in 35% (6/17) of patients with NRAS_mutated melanoma (Sullivan et al., 2018; 29247021). In a Phase 1 study, patients with NRAS_mutated melanoma benefited from treatment with belvarafenib, a type_II RAF inhibitor, with PRs reported in the dose_escalation (44% [4/9]) and dose_expansion (20% [2/10]) cohorts (Yen et al., 2021; 33953400). Retrospective analysis of patients with melanoma treated with first_line nivolumab plus ipilimumab showed significantly improved survival for those with BRAF_mutated disease (9.9 months median PFS [mPFS] and median OS [mOS] not reached) relative to those with either NRAS_mutated disease (4.8 months mPFS and 14.2 months mOS) or disease lacking BRAF and NRAS mutations (5.3 months mPFS and 16.1 months mOS) (van Not et al., 2022; 36130145). In a Phase 1 study evaluating the MEK_pan_RAF dual inhibitor CH5126766, 1 patient harboring an NRAS mutation experienced a PR (Martinez_Garcia et al., 2012; 22761467).", "Include": "true", "ClinicalTrialNote": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Cobimetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Cobimetinib is a MEK inhibitor that is FDA approved to treat patients with histiocytic neoplasms. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors (Abdel_Wahab et al., 2014; 24589925, Ascierto et al., 2013; 23414587, Zimmer et al., 2014; 24947927, van Herpen et al., 2019; 30956763, Van Herpen et al., 2014; ESMO Abstract LBA35, Dummer et al., 2017; 28284557, Slosberg et al., 2018; 29765547, Khanna et al., 2015; 26870618, Goldinger et al., 2019; 31436845, Ravandi et al., 2015; 26657199). </p> <p><b>Supporting Data:</b> Significant clinical responses to various other MEK inhibitors have been documented in NRAS_mutant melanoma (Ascierto et al., 2013; 23414587, Adjei et al., 2008; 18390968, Zimmer et al., 2014; 24947927, Martinez_Garcia et al., 2012; 22761467). Patients with metastatic melanoma and NRAS mutations experienced PRs (26% [5/19]) and SDs (42% [8/19]) in response to cobimetinib combined with the RAF inhibitor belvarafenib (Kim et al., 2021; ESMO Abstract 529P). A Phase 1 study of cobimetinib monotherapy in solid tumors reported 1% (1/97) CR and 6% (6/97) PR, all of which were achieved by patients with melanoma (6 with BRAF V600E) (Rosen et al., 2016; 27424159). Patients with metastatic melanoma treated with cobimetinib combined with the RAF inhibitor belvarafenib experienced PRs for those with BRAF V600 mutations (33% [3/9]) and non_V600 mutations (50% [3/6])(Kim et al., 2021; ESMO Abstract 529P). In the Phase 3 IMspire170 study, the combination of atezolizumab and cobimetinib did not improve median PFS (5.5 vs. 5.7 months), ORR (26% vs. 32%) or 6_month OS (88% vs. 87%) compared with pembrolizumab for patients with previously untreated BRAF V600 wildtype melanoma (Arance et al., 2019; ESMO Abstract LBA69). Similarly, the Phase 2 TRICOTEL trial for patients with BRAF wildtype melanoma with central nervous system metastases reported an intracranial ORR of 27% following combination treatment of atezolizumab and cobimetinib (Dummer et al., 2022; 35940183). A Phase 1b study evaluating the combination of atezolizumab and cobimetinib for the treatment of patients with solid tumors reported an ORR of 41% (9/22) in patients with melanoma, regardless of BRAF status; the 12_month PFS and OS rates were 50% and 85%, respectively (Hellman et al., 2019; 30918950). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Selumetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients with neurofibromatosis type 1 (NF1)_associated plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors (Abdel_Wahab et al., 2014; 24589925, Ascierto et al., 2013; 23414587, Zimmer et al., 2014; 24947927, van Herpen et al., 2019; 30956763, Van Herpen et al., 2014; ESMO Abstract LBA35, Dummer et al., 2017; 28284557, Slosberg et al., 2018; 29765547, Khanna et al., 2015; 26870618, Goldinger et al., 2019; 31436845, Ravandi et al., 2015; 26657199). </p> <p><b>Supporting Data:</b> In a Phase 2 study for patients with metastatic melanoma, selumetinib monotherapy achieved an ORR of 5.8%; among patients with BRAF mutations, the ORR was 11% (5/45) (Kirkwood et al., 2012; 22048237). In a Phase 2 trial of first_line treatment of BRAF_mutated metastatic melanoma, the addition of selumetinib to dacarbazine increased PFS compared to dacarbazine plus placebo (5.6 vs 3.0 months, HR=0.63) but did not significantly improve OS (13.9 vs 10.5 months, HR 0.93, p=0.39) (Robert et al., 2013; 23735514). In a Phase 2 trial for patients with BRAF wildtype advanced melanoma, the addition of selumetinib to docetaxel did not improve median PFS compared to docetaxel plus placebo (4.2 vs 3.9 months) and was associated with lower OS (9.5 months vs 11.4 months); NRAS mutation was associated with inferior OS (HR=0.78) (Gupta et al., 2014; 24567366). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Trametinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors (Abdel_Wahab et al., 2014; 24589925, Ascierto et al., 2013; 23414587, Zimmer et al., 2014; 24947927, van Herpen et al., 2019; 30956763, Van Herpen et al., 2014; ESMO Abstract LBA35, Dummer et al., 2017; 28284557, Slosberg et al., 2018; 29765547, Khanna et al., 2015; 26870618, Goldinger et al., 2019; 31436845, Ravandi et al., 2015; 26657199). </p> <p><b>Supporting Data:</b> One retrospective study of MEK inhibitors in NRAS_mutated melanoma reported an ORR of 23% (5/22) for pretreated patients with trametinib as a single agent (Salzmann et al., 2022; 35272084), although efficacy was limited in a Phase 1 trial of advanced melanoma (0 PRs, 29% DCR [2/7]) (Falchook et al., 2012; 22805292). A real_world study of trametinib with or without anti_PD1 antibodies in immune checkpoint inhibitor (ICI)_resistant melanoma reported PRs for 5% (1/20) of patients with NRAS_mutated disease and a median OS of 6.5 months for the cohort overall (n=22) (Pigne et al., 2023; 36919691). The combination of trametinib with paclitaxel resulted in PRs for 50% (4/8) of patients with melanoma harboring NRAS mutations (Coupe et al., 2015; 25542057). Combination approaches pairing trametinib with other agents are also under investigation in NRAS_mutated melanoma. A Phase 2 study of trametinib and the BRAF/CRAF inhibitor LXH254 reported 1 PR and a DCR of 67% (16/24) for patients with ICI_resistant disease at the expansion dose (Lebbe et al., 2022; ESMO Abstract LBA40), building on a Phase 1b trial reporting an ORR of 47% (7/15) (de Braud et al., 2022; AACR Abstract CT197). A study reported responses for 25% (1/4) of patients with the combination of trametinib and ICIs (Salzmann et al., 2022; 35272084). As a monotherapy for patients with BRAF V600E/K_mutated metastatic melanoma, trametinib improved PFS (4.9 vs. 1.5 months, HR=0.54) and median OS (15.6 vs. 11.3 months, HR=0.84) compared with patients treated with chemotherapy (Robert et al., 2019; 30690294). In a Phase 1 study, 10% (4/40) of patients with BRAF_wildtype metastatic melanoma achieved a PR (Falchook et al., 2012; 22805292). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04913285", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04985604", "Include": "true"}, {"nctId": "NCT04835805", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT05580770", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}, {"nctId": "NCT04892017", "Include": "true"}, {"nctId": "NCT05340621", "Include": "true"}, {"nctId": "NCT04720976", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MUTYH", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 892_2A>G", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "39.8", "isEquivocal": "false", "name": "splice site 892_2A>G"}}, "Interpretation": "MUTYH (also known as MYH) encodes an enzyme involved in DNA base excision repair, and loss of function mutations in MUTYH result in increased rates of mutagenesis and promotion of tumorigenesis (David et al., 2007; 17581577). The two most frequently reported MUTYH loss of function mutations are G382D (also referred to as G396D) and Y165C (also referred to as Y179C) (Molatore et al., 2010; 19953527, Kundu et al., 2009; 19836313, D Agostino et al., 2010; 20418187, Hegde et al., 2014; 24310308, Aretz et al., 2013; 22872101). Numerous other MUTYH mutations have also been shown to result in loss of function (Molatore et al., 2010; 19953527, Kundu et al., 2009; 19836313, Ali et al., 2008; 18534194, D Agostino et al., 2010; 20418187). In general, somatic MUTYH mutations are infrequently reported across cancer types (COSMIC, 2023)(Tate et al., 2019; 30371878). Monoallelic MUTYH mutation occurs in 1_2% of the general population (Hegde et al., 2014; 24310308, Aretz et al., 2013; 22872101). There are conflicting data regarding the impact of monoallelic mutations on the risk of developing colorectal cancer (CRC) (Win et al., 2014; 24444654, Lubbe et al., 2009; 19620482, Jones et al., 2009; 19394335). Patients with MUTYH_mutated CRC were reported to have significantly improved OS compared with patients without MUTYH mutation (Nielsen et al., 2010; 21044966). There are no therapies or clinical trials available to address MUTYH alterations in cancer. One or more of the MUTYH variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with MUTYH_associated polyposis (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline biallelic MUTYH mutation causes MUTYH_associated polyposis (also known as MYH_associated polyposis or MAP), an autosomal recessive condition characterized by multiple colorectal adenomas and increased lifetime risk of colorectal cancer (CRC) (Hegde et al., 2014; 24310308, Sampson et al., 2003; 12853198, Sieber et al., 2003; 12606733, Al_Tassan et al., 2002; 11818965). MAP accounts for approximately 0.7% of all CRC cases and 2% of early_onset CRC cases (Hegde et al., 2014; 24310308). In contrast to CRC, the role of MUTYH mutation in the context of other cancer types is not well established (Rennert et al., 2012; 21952991, Zhang et al., 2006; 16492928, von der Th\u00fcsen et al., 2011; 21189386, Casper et al., 2014; 24420788, Smith et al., 2009; 20110747). Estimates for the prevalence of MAP in the general population range from 1:5,000_1:10,000 (Aretz et al., 2013; 22872101). Therefore, in the appropriate clinical context, germline testing of MUTYH is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been detected in 16_32% of cutaneous melanomas in several small datasets, with the majority exhibiting MSI_low (Kubecek et al., 2016; 27623135). A higher frequency of MSI (low and high) has been reported in metastatic tumors (20_77%) compared to primary tumors (2_30%) (Kubecek et al., 2016; 27372860). No association between MSI status and clinicopathological features of patients with melanoma was reported in one study (Peris et al., 1995; 7561170). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "PRDM1", "Include": "true", "Alterations": {"Alteration": {"Name": "V10fs*10", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "52.48", "isEquivocal": "false", "name": "V10fs*10"}}, "Interpretation": "PRDM1 encodes the transcriptional repressor protein BLIMP_1, which antagonizes expression of beta_interferon, among other genes (Keller and Maniatis, 1991; 1851123). BLIMP_1 plays a key role in mediating terminal differentiation of myeloid cells and B_lymphocytes, in part through repression of c_MYC transcription (Chang et al., 2000; 11248811). Inactivating somatic alterations of PRDM1 have been shown to occur in approximately one quarter of activated B_cell type diffuse large B_cell lymphomas (ABC_DLBCL) but not in other DLBCL subtypes (Pasqualucci et al., 2006; 16492805). In contrast to this tumor suppressor role in lymphoma, BLIMP_1 activity has been hypothesized to promote cell migration and invasion based on cell culture models of lung cancer (Yu et al., 2012; 22438909). There are no targeted therapies available to address genomic alterations in PRDM1.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "SGK1", "Include": "true", "Alterations": {"Alteration": {"Name": "loss exons 1_12", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss exons 1_12"}}, "Interpretation": "SGK1 encodes serum/glucocorticoid regulated kinase 1, which activates ion channels in response to cellular stress. SGK1 can be activated by PI3K_mTORC2 signaling (Garc\u00eda_Mart\u00ednez et al., 2008; 18925875) and can in turn activate mTORC1 (Castel et al., 2016; 27451907). SGK1 mutation has been observed in 6_16% of diffuse large B_cell lymphomas (cBio_Lohr et al., 2012; 22343534), 5/7 cases of variant nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), and 1/6 cases of typical NLPHL (Hartmann et al., 2016; 26658840). SGK1 amplification and mutation have rarely been observed in other tumor types (cBioPortal, COSMIC, 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Increased SGK1 expression has been reported in lung squamous cell carcinoma (Abbruzzese et al., 2012; 22240294), endometrioid endometrial carcinoma (Conza et al., 2017; 28177128), glioblastoma (Talarico et al., 2016; 26908461), and breast cancer (Sahoo et al., 2005; 16246546). The PI3K inhibitor LY294002 has been reported to block SGK1 activity in a preclinical study (Park et al., 1999; 10357815). Several SGK1 inhibitors (Ackermann et al., 2011; 21865856, Castel et al., 2016; 27451907, Halland et al., 2014; 25589934, Mansley et al., 2010; 20880397, O Neill et al., 2015; 26267320, Sherk et al., 2008; 18794135) have been developed but are not suitable for clinical use. SGK1 and NDRG1 expression were reported to be increased in three PIK3CA_mutant breast cancer samples from patients who did not respond to treatment with the PI3K inhibitor BYL719 in combination with aromatase inhibitor (Castel et al., 2016; 27451907). Additionally, preclinical studies have reported that SGK1 expression confers resistance to BYL719 in breast cancer cells harboring PIK3CA activating mutations (Castel et al., 2016; 27451907) and to the AKT inhibitors AZD5363 and MK2206 in breast cancer cells (Sommer et al., 2013; 23581296).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "SMAD2", "Include": "true", "Alterations": {"Alteration": {"Name": "loss exons 7_8", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss exons 7_8"}}, "Interpretation": "SMAD2 encodes an intracellular transducer that is activated by TGF_beta or activin to dimerize with SMAD4 and regulate transcription of TGF_beta or activin_activated genes (Lebrun et al., 1999; 9892009, Lin et al., 2006; 16751101). SMAD2 alterations that disrupt the MH1 domain (amino acids 10_176), MH2 domain (amino acids 274_467), or critical phosphorylation sites are predicted to result in a loss of function (Fleming et al., 2013; 23139211, Funaba et al., 2002; 12193595, Mac\u00edas_Silva et al., 1996; 8980228, Massague et al., 2005; 16322555, Matsuzaki et al., 2009; 19531654, Wu et al., 2012; 22539990). SMAD2 mutations have been reported in various tumor types, including cutaneous squamous cell carcinoma (SCC; 6_10%)(Li et al., 2015; 25589618), colorectal adenocarcinoma (CRC; 3_7%)(Fleming et al., 2013; 23139211, Cancer Genome Atlas Network., 2012; 22810696), endometrial cancers (2_5%)(Cancer Genome Atlas Research Network., 2013; 23636398), stomach adenocarcinoma (2_3%)(Cancer Genome Atlas Research Network., 2014; 25079317), lung SCC (1_2%)(Cancer Genome Atlas Research Network., 2012; 22960745), and lung adenocarcinoma (1_2%)(Cancer Genome Atlas Research Network., 2014; 25079552, cBio_Imielinski et al., 2012; 22980975, Uchida et al., 1996; 8971158, cBio_Ding et al., 2008; 18948947). SMAD2 deletion, as well as loss of expression or phosphorylation (p_SMAD2), has been reported in several cancers (Boulay et al., 2001; 11391794, Xie et al., 2003; 12967141, Koumoundourou et al., 2007; 17695423, Xie et al., 2002; 11809701, Liapis et al., 2007; 17295676, Wu et al., 2007; 17729405, Mac\u00edas_Silva et al., 1996; 8980228) and has been correlated with poor prognosis in hepatocellular, gastric, breast, and colorectal cancer (Xie et al., 2003; 12967141, Koumoundourou et al., 2007; 17695423, Xie et al., 2002; 11809701, Liapis et al., 2007; 17295676, Wu et al., 2007; 17729405) but good prognosis in HNSCC (Xie et al., 2013; 22275186, Mangone et al., 2010; 20462450). There are no therapies that target the loss of SMAD2 or loss of TGF_beta signaling in cancer. Because TGF_beta can exert both tumor suppressor as well as pro_tumor effects, the development of therapies aimed at this pathway must be carefully considered for each patient. In preclinical studies, several novel small_molecule TGF_beta pathway inhibitors have been shown to reduce SMAD2 phosphorylation and tumor invasion in breast cancer cells and to increase survival in mouse xenograft models (Ehata et al., 2007; 17129361, Rausch et al., 2009; 19528470).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TERT", "Include": "true", "Alterations": {"Alteration": {"Name": "promoter _146C>T", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "17.28", "isEquivocal": "false", "name": "promoter _146C>T"}}, "Interpretation": "Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80_90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at _124 bp and _146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions \u2013124/\u2013125 bp and \u2013138/\u2013139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been reported in 22_71% of melanoma cases, including 85% of metastatic melanomas, 66% of unknown primary melanomas, 32% (12/38) of conjunctival melanomas, 13.2% (7/53) of mucosal melanomas, 6% (2/32) of acral lentiginous melanomas, and 1/50 uveal melanomas (Populo et al., 2014; 24691053, Eqberts et al., 2014; 24463461, Huang et al., 2013; 23348506, Horn et al., 2013; 23348503, Liau et al., 2014; 24588324, Scott et al., 2014; 24030752, Griewank et al., 2013; 23799844, Vinagre et al., 2013; 23887589). TERT promoter mutations associate with increased TERT expression in melanoma (Heidenreich et al., 2014; 24569790, Huang et al., 2013; 23348506, Horn et al., 2013; 23348503). Gains of the TERT locus have also been reported in 31.2% (5/16) of melanomas (Puig_Butille et al., 2013; 23362874). TERT promoter mutations or protein overexpression has been associated with poor clinico_pathological features, but not with impact on survival (Populo et al., 2014; 24691053, Eqberts et al., 2014; 24463461, Heidenreich et al., 2014; 24569790, Zygouris et al., 2007; 18067210). In addition, germline polymorphisms in TERT have been associated with risk of melanoma development (Law et al., 2012; 21993562, Yin et al., 2012; 23226346, Nan et al., 2011; 21116649). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor_associated antigen and antisense oligonucleotide_ or peptide_based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti_CTLA_4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non_small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Johnson et al., 2016; 27671167, Goodman et al., 2017; 28835386, Eroglu et al, 2018; 29320474, Shin et al., 2017; 27903500, Riaz et al., 2017; 29033130, Cristescu et al., 2018; 30309915, Samstein et al., 2019; 30643254, Ribas et al., 2019; AACR abstract 4217, Hodi et al., 2019; AACR abstract CT037, Marabelle et al., 2020; 32919529). A large_scale genomic analysis found that various melanoma subtypes harbored median TMBs between 6.3 and 14.4 Muts/Mb, and 25% to 40% of cases had elevated TMBs of greater than 20 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Malignant melanoma has been reported to have a high prevalence of somatic mutations compared with other tumor types (Alexandrov et al., 2013; 23945592), with desmoplastic melanoma ranking among the highest of melanoma subtypes (median TMB of 62 Muts/Mb)(Shain et al., 2015; 26343386). Higher mutational load has been reported in NF1_mutant melanoma samples compared with BRAF_mutant, NRAS_mutant, or BRAF/NRAS/NF1 wild_type samples (Johnson et al., 2016; 27671167). In 1 study, elevated TMB correlated with PD_L1 positive status and increased OS in tissue specimens from patients with Stage 3 melanoma (Madore et al., 2016; 26960397). In another study, elevated tissue TMB (>20 Muts/Mb) was associated with longer PFS and OS in patients treated with anti_PD_1 or anti_PD_L1 immunotherapy as compared with patients with lower TMB (Johnson et al., 2016; 27671167). Increased TMB has also been associated with histologic stage and cumulative sun exposure (Shain et al., 2015; 26559571). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple studies of immune checkpoint inhibitors in melanoma, higher TMB has corresponded with clinical benefit from treatment with anti_PD_1 or anti_PD_L1 treatments (Hodi et al., 2019; AACR Abstract CT037, Ribas et al., 2019; AACR Abstract 4217, Cristescu et al., 2018; 30309915, Johnson et al., 2016; 27671167, Ning et al., 2022; 35355708). Increased TMB has been associated with longer PFS and OS for patients with melanoma treated with nivolumab, with studies reporting increased benefit for patients with a mutational load above 162 missense mutations per tumor (~equivalency >8 Muts/Mb as measured by this assay) (Hodi et al., 2019; AACR abstract CT037). Increased TMB (~equivalency >10.8 Muts/Mb as measured by this assay) has also been associated with longer PFS and OS for patients with melanoma treated with combination nivolumab and ipilumumab (Hodi et al., 2019; AACR abstract CT037). Improved PFS and OS of patients with melanoma treated with ipilumumab has been observed across all TMB levels (Ribas et al., 2019; AACR abstract 4217, Liu et al., 2019; 31515453).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "NRAS", "Alteration": "Q61R", "Title": "A Study to Evaluate KIN_2787 in Subjects With BRAF Mutation Positive Solid Tumors", "StudyPhase": "PHASE 1", "Target": "BRAF, MEK", "Locations": "Taipei (Taiwan), Shanghai (China), Bengbu (China), Wuhan (China), Linyi (China), Gyeonggi_do (Korea, Republic of), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Beijing (China)", "NCTID": "NCT04913285", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRAF, MEK", "Locations": "Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado", "NCTID": "NCT04985604", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS_mutant Advanced Melanoma.", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs, NRAS, PD_L1", "Locations": "Seoul (Korea, Republic of), Nedlands (Australia), Waratah (Australia), Melbourne (Australia), Oslo (Norway), Bergen (Norway), Berlin (Germany), Hamburg (Germany), W\u00fcrzburg (Germany), Mannheim (Germany)", "NCTID": "NCT04835805", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs, NRAS", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "Mirdametinib + BGB_3245 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRAF, MEK", "Locations": "Waratah (Australia), Melbourne (Australia), California, Ohio, Massachusetts, Texas, Connecticut, Florida", "NCTID": "NCT05580770", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "L\u00fcbeck (Germany), W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "A Safety, Tolerability and PK Study of DCC_3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1/2", "Target": "ULK1, ULK2, MEK", "Locations": "Oregon, Massachusetts, New York, Texas, Pennsylvania", "NCTID": "NCT04892017", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "OKI_179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS_mutated Melanoma (Phase 2)", "StudyPhase": "PHASE 1/2", "Target": "HDACs, MEK", "Locations": "California, Michigan, Massachusetts, New York, Tennessee, Virginia, Texas, Georgia, Florida", "NCTID": "NCT05340621", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "JAB_3312 Activity in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MEK, SHP2, PD_1, EGFR, KRAS", "Locations": "Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut", "NCTID": "NCT04720976", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "1", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "2", "ReferenceId": "19966803", "FullCitation": "Cirstea IC, et al. Nat. Genet. (2010) pmid: 19966803", "Include": "true"}, {"number": "3", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "4", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "5", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "6", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "7", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "8", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "9", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "10", "ReferenceId": "21263000", "FullCitation": "Runtuwene V, et al. Dis Model Mech (2011) pmid: 21263000", "Include": "true"}, {"number": "11", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "12", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "13", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "14", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "15", "ReferenceId": "28594414", "FullCitation": "Altm\u00fcller F, et al. Eur J Hum Genet (2017) pmid: 28594414", "Include": "true"}, {"number": "16", "ReferenceId": "26888048", "FullCitation": "Hiippala A, et al. Am. J. Med. Genet. A (2016) pmid: 26888048", "Include": "true"}, {"number": "17", "ReferenceId": "21166657", "FullCitation": "Lee JH, et al. Br. J. Dermatol. (2011) pmid: 21166657", "Include": "true"}, {"number": "18", "ReferenceId": "24755198", "FullCitation": "Xia J, et al. Mol. Cancer Ther. (2014) pmid: 24755198", "Include": "true"}, {"number": "19", "ReferenceId": "23362874", "FullCitation": "Puig_Butill\u00e9 JA, et al. Exp. Dermatol. (2013) pmid: 23362874", "Include": "true"}, {"number": "20", "ReferenceId": "19571822", "FullCitation": "J. Invest. Dermatol. (2010) pmid: 19571822", "Include": "true"}, {"number": "21", "ReferenceId": "22419879", "FullCitation": "Monzon JG, et al. Onco Targets Ther (2012) pmid: 22419879", "Include": "true"}, {"number": "22", "ReferenceId": "19383313", "FullCitation": "Platz A, et al. Mol Oncol (2008) pmid: 19383313", "Include": "true"}, {"number": "23", "ReferenceId": "12429636", "FullCitation": "Omholt K, et al. Clin. Cancer Res. (2002) pmid: 12429636", "Include": "true"}, {"number": "24", "ReferenceId": "23855428", "FullCitation": "Ekedahl H, et al. Br. J. Dermatol. (2013) pmid: 23855428", "Include": "true"}, {"number": "25", "ReferenceId": "23890154", "FullCitation": "Dutton_Regester K, et al. Pigment Cell Melanoma Res (2013) pmid: 23890154", "Include": "true"}, {"number": "26", "ReferenceId": "22180178", "FullCitation": "Jakob JA, et al. Cancer (2012) pmid: 22180178", "Include": "true"}, {"number": "27", "ReferenceId": "23993026", "FullCitation": "Zebary A, et al. J. Dermatol. Sci. (2013) pmid: 23993026", "Include": "true"}, {"number": "28", "ReferenceId": "23633454", "FullCitation": "Griewank KG, et al. Clin. Cancer Res. (2013) pmid: 23633454", "Include": "true"}, {"number": "29", "ReferenceId": "23739925", "FullCitation": "Uhara H, et al. Int. J. Clin. Oncol. (2014) pmid: 23739925", "Include": "true"}, {"number": "30", "ReferenceId": "15917418", "FullCitation": "Wong CW, et al. J. Clin. Pathol. (2005) pmid: 15917418", "Include": "true"}, {"number": "31", "ReferenceId": "24603591", "FullCitation": "Aulmann S, et al. Mod. Pathol. (2014) pmid: 24603591", "Include": "true"}, {"number": "32", "ReferenceId": "31578274", "FullCitation": "Wang HY, et al. Oncologist (2019) pmid: 31578274", "Include": "true"}, {"number": "33", "ReferenceId": "21615881", "FullCitation": "Devitt B, et al. Pigment Cell Melanoma Res (2011) pmid: 21615881", "Include": "true"}, {"number": "34", "ReferenceId": "23673558", "FullCitation": "Birkeland E, et al. Clin. Exp. Metastasis (2013) pmid: 23673558", "Include": "true"}, {"number": "35", "ReferenceId": "22931913", "FullCitation": "Mann GJ, et al. J. Invest. Dermatol. (2013) pmid: 22931913", "Include": "true"}, {"number": "36", "ReferenceId": "21788131", "FullCitation": "Si L, et al. Eur. J. Cancer (2012) pmid: 21788131", "Include": "true"}, {"number": "37", "ReferenceId": "24959217", "FullCitation": "Rutkowski P, et al. Oncol Lett (2014) pmid: 24959217", "Include": "true"}, {"number": "38", "ReferenceId": "24918823", "FullCitation": "Carlino MS, et al. Br. J. Cancer (2014) pmid: 24918823", "Include": "true"}, {"number": "39", "ReferenceId": "24276025", "FullCitation": "Egberts F, et al. Ann. Oncol. (2014) pmid: 24276025", "Include": "true"}, {"number": "40", "ReferenceId": "25048604", "FullCitation": "Wu S, et al. Cancer Causes Control (2014) pmid: 25048604", "Include": "true"}, {"number": "41", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "42", "ReferenceId": "26657199", "FullCitation": "Ravandi F, et al. Blood Cancer J (2015) pmid: 26657199", "Include": "true"}, {"number": "43", "ReferenceId": "30635233", "FullCitation": "Maiti A, et al. Clin Lymphoma Myeloma Leuk (2019) pmid: 30635233", "Include": "true"}, {"number": "44", "ReferenceId": "26870618", "FullCitation": "Khanna V, et al. Cureus (2015) pmid: 26870618", "Include": "true"}, {"number": "45", "ReferenceId": "26228812", "FullCitation": "Heuck CJ, et al. Leukemia (2016) pmid: 26228812", "Include": "true"}, {"number": "46", "ReferenceId": "24589925", "FullCitation": "Abdel_Wahab O, et al. Cancer Discov (2014) pmid: 24589925", "Include": "true"}, {"number": "47", "ReferenceId": "26446942", "FullCitation": "Holkova B, et al. Clin. Cancer Res. (2016) pmid: 26446942", "Include": "true"}, {"number": "48", "ReferenceId": "28284557", "FullCitation": "Dummer R, et al. Lancet Oncol. (2017) pmid: 28284557", "Include": "true"}, {"number": "49", "ReferenceId": "23414587", "FullCitation": "Ascierto PA, et al. Lancet Oncol. (2013) pmid: 23414587", "Include": "true"}, {"number": "50", "ReferenceId": "30956763", "FullCitation": "van Herpen CML, et al. Oncotarget (2019) pmid: 30956763", "Include": "true"}, {"number": "51", "ReferenceId": "29247021", "FullCitation": "Sullivan RJ, et al. Cancer Discov (2018) pmid: 29247021", "Include": "true"}, {"number": "52", "ReferenceId": "33953400", "FullCitation": "Yen I, et al. Nature (2021) pmid: 33953400", "Include": "true"}, {"number": "53", "ReferenceId": "36130145", "FullCitation": "van Not OJ, et al. JCO Precis Oncol (2022) pmid: 36130145", "Include": "true"}, {"number": "54", "ReferenceId": "22761467", "FullCitation": "Martinez_Garcia M, et al. Clin. Cancer Res. (2012) pmid: 22761467", "Include": "true"}, {"number": "55", "ReferenceId": "1851123", "FullCitation": "Keller AD, et al. Genes Dev. (1991) pmid: 1851123", "Include": "true"}, {"number": "56", "ReferenceId": "11248811", "FullCitation": "Chang DH, et al. Nat. Immunol. (2000) pmid: 11248811", "Include": "true"}, {"number": "57", "ReferenceId": "16492805", "FullCitation": "Pasqualucci L, et al. J. Exp. Med. (2006) pmid: 16492805", "Include": "true"}, {"number": "58", "ReferenceId": "22438909", "FullCitation": "Yu Z, et al. PLoS ONE (2012) pmid: 22438909", "Include": "true"}, {"number": "59", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "60", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "61", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "62", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "63", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "64", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "65", "ReferenceId": "27623135", "FullCitation": "Kube\u010dek O, et al. Melanoma Res. (2016) pmid: 27623135", "Include": "true"}, {"number": "66", "ReferenceId": "27372860", "FullCitation": "Kubecek O, et al. Med. Hypotheses (2016) pmid: 27372860", "Include": "true"}, {"number": "67", "ReferenceId": "7561170", "FullCitation": "Peris K, et al. J. Invest. Dermatol. (1995) pmid: 7561170", "Include": "true"}, {"number": "68", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "69", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "70", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "71", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "72", "ReferenceId": "18925875", "FullCitation": "Garc\u00eda_Mart\u00ednez JM, et al. Biochem. J. (2008) pmid: 18925875", "Include": "true"}, {"number": "73", "ReferenceId": "27451907", "FullCitation": "Castel P, et al. Cancer Cell (2016) pmid: 27451907", "Include": "true"}, {"number": "74", "ReferenceId": "22343534", "FullCitation": "Lohr JG, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22343534", "Include": "true"}, {"number": "75", "ReferenceId": "26658840", "FullCitation": "Hartmann S, et al. Leukemia (2016) pmid: 26658840", "Include": "true"}, {"number": "76", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "77", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "78", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "79", "ReferenceId": "22240294", "FullCitation": "Abbruzzese C, et al. J. Exp. Clin. Cancer Res. (2012) pmid: 22240294", "Include": "true"}, {"number": "80", "ReferenceId": "28177128", "FullCitation": "Conza D, et al. J. Cell. Physiol. (2017) pmid: 28177128", "Include": "true"}, {"number": "81", "ReferenceId": "26908461", "FullCitation": "Talarico C, et al. Oncotarget (2016) pmid: 26908461", "Include": "true"}, {"number": "82", "ReferenceId": "16246546", "FullCitation": "Sahoo S, et al. Eur. J. Cancer (2005) pmid: 16246546", "Include": "true"}, {"number": "83", "ReferenceId": "10357815", "FullCitation": "Park J, et al. EMBO J. (1999) pmid: 10357815", "Include": "true"}, {"number": "84", "ReferenceId": "21865856", "FullCitation": "Ackermann TF, et al. Cell. Physiol. Biochem. (2011) pmid: 21865856", "Include": "true"}, {"number": "85", "ReferenceId": "25589934", "FullCitation": "Halland N, et al. ACS Med Chem Lett (2015) pmid: 25589934", "Include": "true"}, {"number": "86", "ReferenceId": "20880397", "FullCitation": "Mansley MK, et al. Br. J. Pharmacol. (2010) pmid: 20880397", "Include": "true"}, {"number": "87", "ReferenceId": "26267320", "FullCitation": "O Neill D, et al. Oncotarget (2015) pmid: 26267320", "Include": "true"}, {"number": "88", "ReferenceId": "18794135", "FullCitation": "Sherk AB, et al. Cancer Res. (2008) pmid: 18794135", "Include": "true"}, {"number": "89", "ReferenceId": "23581296", "FullCitation": "Sommer EM, et al. Biochem. J. (2013) pmid: 23581296", "Include": "true"}, {"number": "90", "ReferenceId": "17581577", "FullCitation": "David SS, et al. Nature (2007) pmid: 17581577", "Include": "true"}, {"number": "91", "ReferenceId": "19953527", "FullCitation": "Molatore S, et al. Hum. Mutat. (2010) pmid: 19953527", "Include": "true"}, {"number": "92", "ReferenceId": "19836313", "FullCitation": "Kundu S, et al. DNA Repair (Amst.) (2009) pmid: 19836313", "Include": "true"}, {"number": "93", "ReferenceId": "20418187", "FullCitation": "D Agostino VG, et al. DNA Repair (Amst.) (2010) pmid: 20418187", "Include": "true"}, {"number": "94", "ReferenceId": "24310308", "FullCitation": "Hegde M, et al. Genet. Med. (2014) pmid: 24310308", "Include": "true"}, {"number": "95", "ReferenceId": "22872101", "FullCitation": "Aretz S, et al. Eur. J. Hum. Genet. (2013) pmid: 22872101", "Include": "true"}, {"number": "96", "ReferenceId": "18534194", "FullCitation": "Ali M, et al. Gastroenterology (2008) pmid: 18534194", "Include": "true"}, {"number": "97", "ReferenceId": "24444654", "FullCitation": "Win AK, et al. Gastroenterology (2014) pmid: 24444654", "Include": "true"}, {"number": "98", "ReferenceId": "19620482", "FullCitation": "Lubbe SJ, et al. J. Clin. Oncol. (2009) pmid: 19620482", "Include": "true"}, {"number": "99", "ReferenceId": "19394335", "FullCitation": "Jones N, et al. Gastroenterology (2009) pmid: 19394335", "Include": "true"}, {"number": "100", "ReferenceId": "21044966", "FullCitation": "Nielsen M, et al. J. Natl. Cancer Inst. (2010) pmid: 21044966", "Include": "true"}, {"number": "101", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "102", "ReferenceId": "12853198", "FullCitation": "Sampson JR, et al. Lancet (2003) pmid: 12853198", "Include": "true"}, {"number": "103", "ReferenceId": "12606733", "FullCitation": "Sieber OM, et al. N. Engl. J. Med. (2003) pmid: 12606733", "Include": "true"}, {"number": "104", "ReferenceId": "11818965", "FullCitation": "Al_Tassan N, et al. Nat. Genet. (2002) pmid: 11818965", "Include": "true"}, {"number": "105", "ReferenceId": "21952991", "FullCitation": "Rennert G, et al. Cancer (2012) pmid: 21952991", "Include": "true"}, {"number": "106", "ReferenceId": "16492928", "FullCitation": "Zhang Y, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16492928", "Include": "true"}, {"number": "107", "ReferenceId": "21189386", "FullCitation": "von der Th\u00fcsen JH, et al. J. Clin. Oncol. (2011) pmid: 21189386", "Include": "true"}, {"number": "108", "ReferenceId": "24420788", "FullCitation": "Casper M, et al. Fam. Cancer (2014) pmid: 24420788", "Include": "true"}, {"number": "109", "ReferenceId": "20110747", "FullCitation": "Smith LM, et al. Pancreatology (2009) pmid: 20110747", "Include": "true"}, {"number": "110", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "111", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "112", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "113", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "114", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "115", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "116", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "117", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "118", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "119", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "120", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "121", "ReferenceId": "27671167", "FullCitation": "Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167", "Include": "true"}, {"number": "122", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "123", "ReferenceId": "29320474", "FullCitation": "Eroglu Z, et al. Nature (2018) pmid: 29320474", "Include": "true"}, {"number": "124", "ReferenceId": "27903500", "FullCitation": "Shin DS, et al. Cancer Discov (2017) pmid: 27903500", "Include": "true"}, {"number": "125", "ReferenceId": "29033130", "FullCitation": "Riaz N, et al. Cell (2017) pmid: 29033130", "Include": "true"}, {"number": "126", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "127", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "128", "ReferenceId": "32919529", "FullCitation": "Lancet Oncol. (2020) pmid: 32919529", "Include": "true"}, {"number": "129", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "130", "ReferenceId": "23945592", "FullCitation": "Alexandrov LB, et al. Nature (2013) pmid: 23945592", "Include": "true"}, {"number": "131", "ReferenceId": "26343386", "FullCitation": "Shain AH, et al. Nat. Genet. (2015) pmid: 26343386", "Include": "true"}, {"number": "132", "ReferenceId": "26960397", "FullCitation": "Madore J, et al. Clin. Cancer Res. (2016) pmid: 26960397", "Include": "true"}, {"number": "133", "ReferenceId": "26559571", "FullCitation": "Shain AH, et al. N. Engl. J. Med. (2015) pmid: 26559571", "Include": "true"}, {"number": "134", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "135", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "136", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "137", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "138", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "139", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "140", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "141", "ReferenceId": "35355708", "FullCitation": "Ning B, et al. Front Pharmacol (2022) pmid: 35355708", "Include": "true"}, {"number": "142", "ReferenceId": "31515453", "FullCitation": "Liu L, et al. Clin. Cancer Res. (2019) pmid: 31515453", "Include": "true"}, {"number": "143", "ReferenceId": "9892009", "FullCitation": "Lebrun JJ, et al. Mol. Endocrinol. (1999) pmid: 9892009", "Include": "true"}, {"number": "144", "ReferenceId": "16751101", "FullCitation": "Lin X, et al. Cell (2006) pmid: 16751101", "Include": "true"}, {"number": "145", "ReferenceId": "23139211", "FullCitation": "Fleming NI, et al. Cancer Res. (2013) pmid: 23139211", "Include": "true"}, {"number": "146", "ReferenceId": "12193595", "FullCitation": "Funaba M, et al. J. Biol. Chem. (2002) pmid: 12193595", "Include": "true"}, {"number": "147", "ReferenceId": "8980228", "FullCitation": "Mac\u00edas_Silva M, et al. Cell (1996) pmid: 8980228", "Include": "true"}, {"number": "148", "ReferenceId": "16322555", "FullCitation": "Massagu\u00e9 J, et al. Genes Dev. (2005) pmid: 16322555", "Include": "true"}, {"number": "149", "ReferenceId": "19531654", "FullCitation": "Matsuzaki K, et al. Cancer Res. (2009) pmid: 19531654", "Include": "true"}, {"number": "150", "ReferenceId": "22539990", "FullCitation": "Wu Y, et al. PLoS ONE (2012) pmid: 22539990", "Include": "true"}, {"number": "151", "ReferenceId": "25589618", "FullCitation": "Li YY, et al. Clin. Cancer Res. (2015) pmid: 25589618", "Include": "true"}, {"number": "152", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "153", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "154", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "155", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "156", "ReferenceId": "8971158", "FullCitation": "Uchida K, et al. Cancer Res. (1996) pmid: 8971158", "Include": "true"}, {"number": "157", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "158", "ReferenceId": "11391794", "FullCitation": "Boulay JL, et al. Genes Chromosomes Cancer (2001) pmid: 11391794", "Include": "true"}, {"number": "159", "ReferenceId": "12967141", "FullCitation": "Xie W, et al. Cancer J () pmid: 12967141", "Include": "true"}, {"number": "160", "ReferenceId": "17695423", "FullCitation": "Koumoundourou D, et al. Anticancer Res. () pmid: 17695423", "Include": "true"}, {"number": "161", "ReferenceId": "11809701", "FullCitation": "Xie W, et al. Cancer Res. (2002) pmid: 11809701", "Include": "true"}, {"number": "162", "ReferenceId": "17295676", "FullCitation": "Liapis G, et al. APMIS (2007) pmid: 17295676", "Include": "true"}, {"number": "163", "ReferenceId": "17729405", "FullCitation": "Wu SK, et al. World J. Gastroenterol. (2007) pmid: 17729405", "Include": "true"}, {"number": "164", "ReferenceId": "22275186", "FullCitation": "Xie W, et al. Head Neck (2013) pmid: 22275186", "Include": "true"}, {"number": "165", "ReferenceId": "20462450", "FullCitation": "Mangone FR, et al. Mol. Cancer (2010) pmid: 20462450", "Include": "true"}, {"number": "166", "ReferenceId": "17129361", "FullCitation": "Ehata S, et al. Cancer Sci. (2007) pmid: 17129361", "Include": "true"}, {"number": "167", "ReferenceId": "19528470", "FullCitation": "Rausch MP, et al. Anticancer Res. (2009) pmid: 19528470", "Include": "true"}, {"number": "168", "ReferenceId": "22015685", "FullCitation": "Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685", "Include": "true"}, {"number": "169", "ReferenceId": "9282118", "FullCitation": "Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118", "Include": "true"}, {"number": "170", "ReferenceId": "7605428", "FullCitation": "Kim NW, et al. Science (1994) pmid: 7605428", "Include": "true"}, {"number": "171", "ReferenceId": "10647931", "FullCitation": "Hanahan D, et al. Cell (2000) pmid: 10647931", "Include": "true"}, {"number": "172", "ReferenceId": "23348503", "FullCitation": "Horn S, et al. Science (2013) pmid: 23348503", "Include": "true"}, {"number": "173", "ReferenceId": "23348506", "FullCitation": "Huang FW, et al. Science (2013) pmid: 23348506", "Include": "true"}, {"number": "174", "ReferenceId": "23887589", "FullCitation": "Vinagre J, et al. Nat Commun (2013) pmid: 23887589", "Include": "true"}, {"number": "175", "ReferenceId": "24691053", "FullCitation": "P\u00f3pulo H, et al. J. Invest. Dermatol. (2014) pmid: 24691053", "Include": "true"}, {"number": "176", "ReferenceId": "24463461", "FullCitation": "Egberts F, et al. Melanoma Res. (2014) pmid: 24463461", "Include": "true"}, {"number": "177", "ReferenceId": "24588324", "FullCitation": "Liau JY, et al. J. Cutan. Pathol. (2014) pmid: 24588324", "Include": "true"}, {"number": "178", "ReferenceId": "24030752", "FullCitation": "Scott GA, et al. Mod. Pathol. (2014) pmid: 24030752", "Include": "true"}, {"number": "179", "ReferenceId": "23799844", "FullCitation": "Griewank KG, et al. Br. J. Cancer (2013) pmid: 23799844", "Include": "true"}, {"number": "180", "ReferenceId": "24569790", "FullCitation": "Heidenreich B, et al. Nat Commun (2014) pmid: 24569790", "Include": "true"}, {"number": "181", "ReferenceId": "18067210", "FullCitation": "Zygouris P, et al. J BUON () pmid: 18067210", "Include": "true"}, {"number": "182", "ReferenceId": "21993562", "FullCitation": "Law MH, et al. J. Invest. Dermatol. (2012) pmid: 21993562", "Include": "true"}, {"number": "183", "ReferenceId": "23226346", "FullCitation": "Yin J, et al. PLoS ONE (2012) pmid: 23226346", "Include": "true"}, {"number": "184", "ReferenceId": "21116649", "FullCitation": "Nan H, et al. Hum. Genet. (2011) pmid: 21116649", "Include": "true"}, {"number": "185", "ReferenceId": "27245281", "FullCitation": "Nat Rev Clin Oncol (2017) pmid: 27245281", "Include": "true"}, {"number": "186", "ReferenceId": "29249395", "FullCitation": "Duperret EK, et al. Mol Ther (2018) pmid: 29249395", "Include": "true"}, {"number": "187", "ReferenceId": "25467017", "FullCitation": "Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017", "Include": "true"}, {"number": "188", "ReferenceId": "35940183", "FullCitation": "Dummer R, et al. Lancet Oncol (2022) pmid: 35940183", "Include": "true"}, {"number": "189", "ReferenceId": "30918950", "FullCitation": "Hellmann MD, et al. Ann. Oncol. (2019) pmid: 30918950", "Include": "true"}, {"number": "190", "ReferenceId": "27424159", "FullCitation": "Rosen LS, et al. Invest New Drugs (2016) pmid: 27424159", "Include": "true"}, {"number": "191", "ReferenceId": "18390968", "FullCitation": "Adjei AA, et al. J. Clin. Oncol. (2008) pmid: 18390968", "Include": "true"}, {"number": "192", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "193", "ReferenceId": "31436845", "FullCitation": "Goldinger SM, et al. Br. J. Dermatol. (2020) pmid: 31436845", "Include": "true"}, {"number": "194", "ReferenceId": "22048237", "FullCitation": "Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237", "Include": "true"}, {"number": "195", "ReferenceId": "23735514", "FullCitation": "Robert C, et al. Lancet Oncol. (2013) pmid: 23735514", "Include": "true"}, {"number": "196", "ReferenceId": "24567366", "FullCitation": "Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366", "Include": "true"}, {"number": "197", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "198", "ReferenceId": "30690294", "FullCitation": "Robert C, et al. Eur J Cancer (2019) pmid: 30690294", "Include": "true"}, {"number": "199", "ReferenceId": "22805292", "FullCitation": "Falchook GS, et al. Lancet Oncol. (2012) pmid: 22805292", "Include": "true"}, {"number": "200", "ReferenceId": "35272084", "FullCitation": "Salzmann M, et al. Eur J Cancer (2022) pmid: 35272084", "Include": "true"}, {"number": "201", "ReferenceId": "36919691", "FullCitation": "Pign\u00e9 T, et al. Melanoma Res (2023) pmid: 36919691", "Include": "true"}, {"number": "202", "ReferenceId": "25542057", "FullCitation": "Coupe N, et al. Eur. J. Cancer (2015) pmid: 25542057", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_06_20 23:53:55", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "819x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SKIN", "disease_ontology": "Skin melanoma", "flowcell_analysis": "2000029547", "gender": "female", "pathology_diagnosis": "Melanoma, C43", "percent_tumor_nuclei": "20", "pipeline_version": "v3.23.0", "purity_assessment": "16.27", "specimen": "ORD_1648390_01*US1572225.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1648390_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Lymph Node", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "825.11", "name": "SQ_US1572225.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.593", "cds_effect": "1873G>A", "depth": "602", "equivocal": "false", "functional_effect": "missense", "gene": "PARP1", "percent_reads": "59.3", "position": "chr1:226564877", "protein_effect": "A625T", "status": "unknown", "strand": "_", "transcript": "NM_001618", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.398", "cds_effect": "892_2A>G", "depth": "1078", "equivocal": "false", "functional_effect": "splice", "gene": "MUTYH", "percent_reads": "39.8", "position": "chr1:45797760", "protein_effect": "splice site 892_2A>G", "status": "likely", "strand": "_", "transcript": "NM_001048171", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.4859", "cds_effect": "806C>A", "depth": "601", "equivocal": "false", "functional_effect": "missense", "gene": "KDM5A", "percent_reads": "48.59", "position": "chr12:464388", "protein_effect": "T269N", "status": "unknown", "strand": "_", "transcript": "NM_001042603", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.4894", "cds_effect": "638_639insTGGCGGGGG", "depth": "141", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "LTK", "percent_reads": "48.94", "position": "chr15:41804033", "protein_effect": "G213_A214insGGG", "status": "unknown", "strand": "_", "transcript": "NM_002344", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.5058", "cds_effect": "8399C>T", "depth": "1026", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "50.58", "position": "chr1:16261134", "protein_effect": "A2800V", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.1728", "cds_effect": "_146C>T", "depth": "162", "equivocal": "false", "functional_effect": "promoter", "gene": "TERT", "percent_reads": "17.28", "position": "chr5:1295250", "protein_effect": "promoter _146C>T", "status": "known", "strand": "_", "transcript": "NM_198253", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.4543", "cds_effect": "263A>G", "depth": "656", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3C2G", "percent_reads": "45.43", "position": "chr12:18435278", "protein_effect": "E88G", "status": "unknown", "strand": "+", "transcript": "NM_004570", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.5248", "cds_effect": "29_30delTG", "depth": "505", "equivocal": "false", "functional_effect": "frameshift", "gene": "PRDM1", "percent_reads": "52.48", "position": "chr6:106534456", "protein_effect": "V10fs*10", "status": "likely", "strand": "+", "transcript": "NM_001198", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.164", "cds_effect": "182A>G", "depth": "628", "equivocal": "false", "functional_effect": "missense", "gene": "NRAS", "percent_reads": "16.4", "position": "chr1:115256529", "protein_effect": "Q61R", "status": "known", "strand": "_", "transcript": "NM_002524", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.1467", "cds_effect": "1351G>A", "depth": "518", "equivocal": "false", "functional_effect": "missense", "gene": "SNCAIP", "percent_reads": "14.67", "position": "chr5:121776378", "protein_effect": "D451N", "status": "unknown", "strand": "+", "transcript": "NM_005460", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.4798", "cds_effect": "3820G>A", "depth": "619", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "47.98", "position": "chr2:29432668", "protein_effect": "A1274T", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.054", "cds_effect": "1010C>T", "depth": "648", "equivocal": "false", "functional_effect": "missense", "gene": "DNMT3A", "percent_reads": "5.4", "position": "chr2:25470464", "protein_effect": "S337L", "status": "unknown", "strand": "_", "transcript": "NM_022552", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"allele_fraction": "0.1077", "cds_effect": "2941C>T", "depth": "483", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3C2G", "percent_reads": "10.77", "position": "chr12:18656262", "protein_effect": "R981C", "status": "unknown", "strand": "+", "transcript": "NM_004570", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "0", "equivocal": "false", "gene": "SGK1", "number_of_exons": "14 of 17", "position": "chr6:134491405_134498960", "ratio": "0.82", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "SMAD2", "number_of_exons": "2 of 10", "position": "chr18:45374845_45377733", "ratio": "0.62", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1572225.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.21", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}